Galapagos NV

Galapagos increases share capital through subscription right exercises

07 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

SELECTION study on filgotinib in ulcerative colitis published in The Lancet

04 Jun 2021 00:01:00 By Nasdaq GlobeNewswire

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

27 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

18 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos refocuses pipeline and rightsizes operations  

06 May 2021 15:01:00 By Nasdaq GlobeNewswire

Transparency notification received from The Capital Group

04 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

30 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

22 Apr 2021 23:01:00 By Nasdaq GlobeNewswire

Extension of lock-up period in Gilead-Galapagos collaboration agreement

08 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Publication of the annual report and invitation to the ordinary shareholders’ meeting

25 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Bart Filius as President and Chief Operating Officer

24 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

19 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

04 Mar 2021 00:49:18 By Nasdaq GlobeNewswire

Transparency notification received from The Capital Group

03 Mar 2021 15:15:00 By Nasdaq GlobeNewswire

Pipeline and capital for growth

18 Feb 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

10 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

The Capital Group holds 10.03% of Galapagos shares

09 Feb 2021 15:01:01 By Nasdaq GlobeNewswire

NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis

21 Jan 2021 01:08:24 By Nasdaq GlobeNewswire

Gilead holds 25.54% of Galapagos shares

11 Jan 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference

06 Jan 2021 08:30:00 By Nasdaq GlobeNewswire